Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer-Reference-Cited by-同舟云学术

Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer

Published:2016-11 Issue:5 Volume:70 Page:724-731
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Rescigno Pasquale,Lorente David,Bianchini Diletta,Ferraldeschi Roberta,Kolinsky Michael P.,Sideris Spyridon,Zafeiriou Zafeiris,Sumanasuriya Semini,Smith Alan D.,Mehra Niven,Jayaram Anuradha,Perez-Lopez Raquel,Mateo Joaquin,Parker Chris,Dearnaley David P.,Tunariu Nina,Reid Alison,Attard Gerhardt,de Bono Johann S.

Publisher

Elsevier BV

Subject

Urology

Reference27 articles.

1. Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer;Edwards;Cancer,2014

2. Natural history of progression after PSA elevation following radical prostatectomy;Pound;JAMA,1999

3. Endocrine therapy for prostate cancer;Damber;Acta Oncol,2005

4. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms;Omlin;Eur Urol,2013

5. Clinical states in prostate cancer: toward a dynamic model of disease progression;Scher;Urology,2000

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abiraterone Acetate Versus Enzalutamide Against Chemo-Naïve Castration-Resistant Prostate Cancer With Full-Dose Induction;Cureus;2024-07-10

2. Do Indian men have similar oncological outcomes with abiraterone plus androgen deprivation therapy in the setting of metastatic hormone-sensitive prostate cancer? A prospective observational study;Indian Journal of Urology;2024-07

3. Docetaxel versus androgen receptor signaling inhibitor (ARSI) against chemo-naïve castration-resistant prostate cancer (CRPC): propensity score matched analysis in real world;International Urology and Nephrology;2024-06-24

4. Abiraterone acetate versus enzalutamide against chemo-naïve castration resistant prostate cancer with full dose induction;2024-04-18

5. Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysis;International Journal of Clinical Oncology;2023-12-16